Loading…
Recursion Pharmaceuticals, Inc. is projected to rise to $4.31 by 2027, a +21% move from its current price of $3.56. RXRX is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $3.45 | $3.56 | $3.68 | +0.08% |
| Jul 14 | $3.40 | $3.57 | $3.74 | +0.17% |
| Jul 15 | $3.37 | $3.57 | $3.78 | +0.25% |
| Jul 16 | $3.34 | $3.57 | $3.82 | +0.33% |
| Jul 17 | $3.32 | $3.57 | $3.85 | +0.41% |
| Jul 18 | $3.30 | $3.58 | $3.88 | +0.50% |
| Jul 19 | $3.28 | $3.58 | $3.91 | +0.58% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $3.28 | $3.58 | $3.91 | +0.58% |
| Week 2 | $3.18 | $3.60 | $4.08 | +1.16% |
| Week 3 | $3.11 | $3.62 | $4.22 | +1.75% |
| Week 4 | $3.05 | $3.64 | $4.35 | +2.34% |
| Week 5 | $3.01 | $3.66 | $4.47 | +2.93% |
| Week 6 | $2.97 | $3.69 | $4.58 | +3.53% |
| Week 7 | $2.93 | $3.71 | $4.69 | +4.13% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology.
Its preclinical stage product includes REC-7735 for the treatment of HR+ breast cancer; and REC-102 for the treatment of hypophosphatasia. The company has collaboration and agreement with Roche & Genentech; Sanofi; Bayer AG; Tempus; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc.
was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Recursion Pharmaceuticals, RXRX, is a clinical-stage biotechnology company focused on decoding biology and chemistry to industrialize drug discovery. The stock trades with a current price of $3.57 and a market capitalization of $1.89B, ranking 2080 by market cap. The stock market position and the magnitude of the current price imply a scenario where near-term price action remains sensitive to technical momentum and broader market conditions.
The forecast indicates a multi-year upside with bullish sentiment returning in the later years, supported by rising average prices in the long horizon.
A major floor 27.0% below — a decisive break under it would weaken the trend.
The nearest floor, 14.6% below — buyers have tended to step in here.
The nearest ceiling, 11.2% above — a clean break opens room to run.
A major ceiling 24.7% above — clearing it would confirm fresh momentum.
Key RXRX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of RXRX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $3.77 | Sell | $3.69 | Sell |
| MA 10 | $3.72 | Sell | $3.66 | Sell |
| MA 20 | $3.46 | Buy | $3.55 | Buy |
| MA 50 | $3.35 | Buy | $3.45 | Buy |
| MA 100 | $3.38 | Buy | $3.56 | Buy |
| MA 200 | $4.07 | Sell | $4.00 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 51.95 | Neutral |
| Stoch RSI (14) | 23.59 | Neutral |
| CCI (20) | 25.66 | Neutral |
| Williams %R (14) | -50.00 | Info |
| MACD (12,26,9) | 0.02 | Buy |
| ROC (12) | 12.66 | Buy |
| Bollinger %B (20,2) | 0.59 | Neutral |
| Stochastic %K (14) | 50.00 | Neutral |
| TRIX (15) | 0.44 | Buy |
| Awesome (5,34) | 0.35 | Buy |
| Ultimate (7,14,28) | 49.25 | Neutral |
| Momentum (10) | 0.22 | Buy |
| Aroon Osc (25) | 64.00 | Buy |
| Hull MA (9) | 3.72 | Sell |
| ADX (14) | 15.47 | Neutral |
| ATR (14) | 0.11 | Info |
The 30-day technical picture shows a bullish tilt in sentiment with RSI14 at 50. The SMA50 stands at $3.35, below the SMA200 of $4.07, indicating near-term momentum remains between the shorter and longer moving averages. A support level is identified at $3.04 and a resistance at $3.96, with a 30-day price range from $2.86 to $4.45.
The stock's annualized volatility runs at 60%, highlighting notable but manageable price swings in the near term.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.84 | $3.56 | $5.20 | 0% | Neutral | |
| $3.36 | $4.31 | $5.89 | +21% | Bullish | |
| $3.76 | $4.99 | $7.13 | +40% | Bullish | |
| $3.58 | $4.89 | $7.23 | +37% | Bullish | |
| $3.43 | $4.81 | $7.32 | +35% | Bullish | |
| $3.68 | $5.29 | $8.24 | +48% | Bullish | |
| $4.01 | $5.90 | $9.40 | +66% | Bullish | |
| $4.85 | $7.29 | $11.85 | +105% | Bullish | |
| $5.14 | $7.88 | $13.06 | +121% | Bullish | |
| $5.06 | $7.91 | $13.33 | +122% | Bullish | |
| $6.78 | $11.57 | $20.93 | +225% | Bullish | |
| $9.94 | $19.85 | $39.78 | +457% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $2.84 | $3.56 | $4.44 | +0.00% |
| August 2026 | $3.26 | $3.87 | $4.73 | +8.66% |
| September 2026 | $3.20 | $3.84 | $4.76 | -0.78% |
| October 2026 | $3.21 | $3.88 | $4.86 | +1.01% |
| November 2026 | $3.33 | $4.05 | $5.12 | +4.36% |
| December 2026 | $3.33 | $4.07 | $5.20 | +0.64% |
Click any year to see its month-by-month RXRX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect RXRX to range from $2.84 to $5.20 through 2026. The $3.56 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The RXRX price prediction for 2027 points to an average of $4.31 (low $3.36, high $5.89) — a potential gain of +21% on today's $3.56. Momentum favours further upside here.
In 2028, RXRX is projected to trade between $3.76 and $7.13, averaging $4.99 — a potential gain of +40% from today's $3.56. That is up +16% on the projected 2027 average. Buyers look set to stay in control over this stretch.
Recursion Pharmaceuticals, Inc.'s 2029 outlook centres on $4.89, within a $3.58 to $7.23 range. That is -2% versus the projected 2028 average. That marks a +37% change versus current levels. Momentum favours further upside here.
By 2030, RXRX could reach as high as $7.32, with a base case around $4.81 and support toward $3.43 — roughly +35% from $3.56. Buyers look set to stay in control over this stretch.
Expect RXRX to range from $3.68 to $8.24 through 2031. The $5.29 average target implies a +48% move from current prices. That is up +10% on the projected 2030 average. Momentum favours further upside here.
The RXRX price prediction for 2032 points to an average of $5.90 (low $4.01, high $9.40) — a potential gain of +66% on today's $3.56. Buyers look set to stay in control over this stretch.
In 2033, RXRX is projected to trade between $4.85 and $11.85, averaging $7.29 — a potential gain of +105% from today's $3.56. That is up +24% on the projected 2032 average. Momentum favours further upside here.
Recursion Pharmaceuticals, Inc.'s 2034 outlook centres on $7.88, within a $5.14 to $13.06 range. That is up +8% on the projected 2033 average. That marks a +121% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, RXRX could reach as high as $13.33, with a base case around $7.91 and support toward $5.06 — roughly +122% from $3.56. Momentum favours further upside here.
Expect RXRX to range from $6.78 to $20.93 through 2040. The $11.57 average target implies a +225% move from current prices. That is up +46% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The RXRX price prediction for 2050 points to an average of $19.85 (low $9.94, high $39.78) — a potential gain of +457% on today's $3.56. Momentum favours further upside here.
Investing $1,000 in RXRX today (≈ 280.898876 RXRX) could be worth
$5,574.91
+$4,574.91 (+457%) by 2050 · US Dollar
Based on the average projected RXRX price of $19.85 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in RXRXwould be worth at today's price.
$1,000 invested in RXRX on Jul 10, 2025 (≈ 174.978123 RXRX) would be worth
$622.92
-$377.08 (-37.7%) today · 0.62× · US Dollar
Based on a RXRX entry price of $5.72 vs. today's $3.56.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $3.8 | $936.84 | -6.3% |
| 1 month ago | $3.04 | $1,171.05 | +17.1% |
| 3 months ago | $3.28 | $1,085.37 | +8.5% |
| 6 months ago | $4.81 | $740.12 | -26.0% |
| 1 year ago | $5.72 | $622.92 | -37.7% |
| All time (5.0y) ago | $41.33 | $86.14 | -91.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our RXRX forecast.
Our base-case forecast reaches $7.10 around 2033.
Implied market cap at $7.10: $3.73B
Looking across the multi-year forecast, the average price rises from $3.57 in 2026 to higher levels over the coming years. In 2026 the avg is $3.57 with a min of $2.84 and a max of $5.21. By 2027 the avg is $4.32 with a max of $5.91 and a bullish sentiment.
In 2028 the avg is $5.01 and in 2029 $4.90, with sentiment remaining bullish. The 2030 avg is $4.82 and the max $7.33, with a bullish outlook and a 35.1% ROI. The forecast continues higher, with 2031 avg $5.31; 2032 avg $5.91; 2033 avg $7.31 (max $11.89, ROI 104.7%), 2034 avg $7.91 (max $13.11, ROI 121.6%), and 2035 avg $7.92 (max $13.35, ROI 121.9%).
By 2040 the avg price is $11.62 (max $21.02) with ROI 225.4% and bullish sentiment, and by 2050 the avg price is $19.88 (max $39.84) with ROI 456.8% and bullish sentiment.
Tap a question to reveal the answer.
The forecast shows an average price of $4.82 in 2030, with a high around $7.33 and a return on investment of 35.1%. The sentiment is bullish for that year.
The forecast shows a transition from neutral in 2026 to bullish from 2027 onward, with rising averages: 2027 average $4.32, 2028 $5.01, 2029 $4.90, and 2030 $4.82, ending 2035 near $7.92. These are estimates and come with uncertainty.
Yes, the 2033 forecast includes a max of $11.89, indicating a path above $10 is possible within the stated outlook.
RXRX trades at $3.57 with a market capitalization of $1.89B.
The 2040 forecast shows an average price of $11.62, a high of $21.02, and a projected ROI of 225.4%, with bullish sentiment.
Recursion Pharmaceuticals, Inc. Community Discussion
0Share your Recursion Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.